单位：[1]Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Clinical Epidemiology and EBM Unit and Liver Research Center, Beijing Friendship Hospital, National Clinical Research Center of Digestive Diseases, Capital Medical University, Beijing 100050, People’s Republic of China临床科室国家中心肝病分中心医技科室北京市临床医学研究所国家消化中心（方法学平台）首都医科大学附属北京友谊医院
第一作者单位：[1]Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, Clinical Epidemiology and EBM Unit and Liver Research Center, Beijing Friendship Hospital, National Clinical Research Center of Digestive Diseases, Capital Medical University, Beijing 100050, People’s Republic of China
通讯作者：
推荐引用方式(GB/T 7714)：
Kong Yuanyuan,You Hong,Jia Jidong.Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense[J].HEPATOLOGY INTERNATIONAL.2016,10(2):239-241.doi:10.1007/s12072-016-9714-9.
APA：
Kong, Yuanyuan,You, Hong&Jia, Jidong.(2016).Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense.HEPATOLOGY INTERNATIONAL,10,(2)
MLA：
Kong, Yuanyuan,et al."Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense".HEPATOLOGY INTERNATIONAL 10..2(2016):239-241
医学